vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and REGIS CORP (RGS). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $57.1M, roughly 1.4× REGIS CORP). REGIS CORP runs the higher net margin — 0.8% vs -9.6%, a 10.4% gap on every dollar of revenue. On growth, REGIS CORP posted the faster year-over-year revenue change (22.3% vs -16.8%). Over the past eight quarters, REGIS CORP's revenue compounded faster (7.8% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Regis Corporation is an American operator of hair salons. As of August 2021, it has 5,563 franchised and 276 company-owned salons. Its headquarters are in Minneapolis, Minnesota.

BIOX vs RGS — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.4× larger
BIOX
$77.6M
$57.1M
RGS
Growing faster (revenue YoY)
RGS
RGS
+39.1% gap
RGS
22.3%
-16.8%
BIOX
Higher net margin
RGS
RGS
10.4% more per $
RGS
0.8%
-9.6%
BIOX
Faster 2-yr revenue CAGR
RGS
RGS
Annualised
RGS
7.8%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q2 FY2026

Metric
BIOX
BIOX
RGS
RGS
Revenue
$77.6M
$57.1M
Net Profit
$-7.4M
$456.0K
Gross Margin
46.8%
Operating Margin
9.3%
10.8%
Net Margin
-9.6%
0.8%
Revenue YoY
-16.8%
22.3%
Net Profit YoY
-20.2%
-94.0%
EPS (diluted)
$-0.12
$0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
RGS
RGS
Q4 25
$57.1M
Q3 25
$77.6M
$59.0M
Q2 25
$60.4M
Q1 25
$60.6M
$57.0M
Q4 24
$98.8M
$46.7M
Q3 24
$93.3M
$46.1M
Q2 24
$49.4M
Q1 24
$84.0M
$49.2M
Net Profit
BIOX
BIOX
RGS
RGS
Q4 25
$456.0K
Q3 25
$-7.4M
$1.4M
Q2 25
$116.5M
Q1 25
$-1.6M
$250.0K
Q4 24
$605.2K
$7.6M
Q3 24
$-6.2M
$-853.0K
Q2 24
$91.2M
Q1 24
$9.8M
$-2.3M
Gross Margin
BIOX
BIOX
RGS
RGS
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Operating Margin
BIOX
BIOX
RGS
RGS
Q4 25
10.8%
Q3 25
9.3%
10.0%
Q2 25
12.1%
Q1 25
1.5%
8.8%
Q4 24
14.5%
11.8%
Q3 24
2.5%
4.6%
Q2 24
Q1 24
15.7%
8.3%
Net Margin
BIOX
BIOX
RGS
RGS
Q4 25
0.8%
Q3 25
-9.6%
2.3%
Q2 25
192.9%
Q1 25
-2.6%
0.4%
Q4 24
0.6%
16.4%
Q3 24
-6.6%
-1.9%
Q2 24
184.7%
Q1 24
11.6%
-4.7%
EPS (diluted)
BIOX
BIOX
RGS
RGS
Q4 25
$0.16
Q3 25
$-0.12
$0.49
Q2 25
$43.67
Q1 25
$-0.02
$0.08
Q4 24
$0.00
$2.71
Q3 24
$-0.10
$-0.36
Q2 24
$38.40
Q1 24
$0.14
$-1.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
RGS
RGS
Cash + ST InvestmentsLiquidity on hand
$15.5M
$18.4M
Total DebtLower is stronger
$113.3M
Stockholders' EquityBook value
$288.3M
$188.7M
Total Assets
$734.9M
$588.3M
Debt / EquityLower = less leverage
0.60×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
RGS
RGS
Q4 25
$18.4M
Q3 25
$15.5M
$16.6M
Q2 25
$17.0M
Q1 25
$38.5M
$13.3M
Q4 24
$29.2M
$10.2M
Q3 24
$32.3M
$6.3M
Q2 24
$10.1M
Q1 24
$16.4M
$5.9M
Total Debt
BIOX
BIOX
RGS
RGS
Q4 25
$113.3M
Q3 25
$111.3M
Q2 25
$110.8M
Q1 25
$112.0M
Q4 24
$111.5M
Q3 24
$95.2M
Q2 24
$99.5M
Q1 24
$179.7M
Stockholders' Equity
BIOX
BIOX
RGS
RGS
Q4 25
$188.7M
Q3 25
$288.3M
$187.6M
Q2 25
$185.6M
Q1 25
$345.0M
$68.6M
Q4 24
$346.3M
$66.7M
Q3 24
$346.0M
$56.4M
Q2 24
$56.8M
Q1 24
$348.5M
$-35.8M
Total Assets
BIOX
BIOX
RGS
RGS
Q4 25
$588.3M
Q3 25
$734.9M
$592.1M
Q2 25
$599.0M
Q1 25
$798.2M
$511.2M
Q4 24
$835.2M
$530.1M
Q3 24
$827.3M
$508.9M
Q2 24
$530.5M
Q1 24
$836.1M
$543.7M
Debt / Equity
BIOX
BIOX
RGS
RGS
Q4 25
0.60×
Q3 25
0.59×
Q2 25
0.60×
Q1 25
1.63×
Q4 24
1.67×
Q3 24
1.69×
Q2 24
1.75×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
RGS
RGS
Operating Cash FlowLast quarter
$14.4M
$1.7M
Free Cash FlowOCF − Capex
$891.0K
FCF MarginFCF / Revenue
1.6%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
3.65×
TTM Free Cash FlowTrailing 4 quarters
$14.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
RGS
RGS
Q4 25
$1.7M
Q3 25
$14.4M
$2.3M
Q2 25
$6.8M
Q1 25
$23.3M
$6.2M
Q4 24
$-5.4M
$2.1M
Q3 24
$5.2M
$-1.3M
Q2 24
$5.1M
Q1 24
$-17.4M
$-277.0K
Free Cash Flow
BIOX
BIOX
RGS
RGS
Q4 25
$891.0K
Q3 25
$1.9M
Q2 25
$6.2M
Q1 25
$5.9M
Q4 24
$1.7M
Q3 24
$-1.4M
Q2 24
$5.1M
Q1 24
$-326.0K
FCF Margin
BIOX
BIOX
RGS
RGS
Q4 25
1.6%
Q3 25
3.2%
Q2 25
10.3%
Q1 25
10.3%
Q4 24
3.6%
Q3 24
-3.0%
Q2 24
10.3%
Q1 24
-0.7%
Capex Intensity
BIOX
BIOX
RGS
RGS
Q4 25
1.4%
Q3 25
0.7%
Q2 25
0.9%
Q1 25
0.6%
Q4 24
0.9%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.1%
Cash Conversion
BIOX
BIOX
RGS
RGS
Q4 25
3.65×
Q3 25
1.68×
Q2 25
0.06×
Q1 25
24.80×
Q4 24
-8.85×
0.28×
Q3 24
Q2 24
0.06×
Q1 24
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

RGS
RGS

Franchise Segment$37.9M66%
Royalty$13.6M24%
Other$2.8M5%
Fees$1.8M3%
Franchise Fees$1.0M2%

Related Comparisons